Non-Muscle Invasive Bladder Cancer (NMIBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Non-Muscle Invasive Bladder Cancer (NMIBC) Market Outlook
Thelansis’s “Non-Muscle Invasive
Bladder Cancer (NMIBC) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Non-Muscle
Invasive Bladder Cancer (NMIBC) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Non-Muscle Invasive Bladder Cancer
(NMIBC) Overview
Non-muscle
invasive bladder cancer (NMIBC) comprises the majority, approximately 80%, of
all bladder cancer cases. Among NMIBC, Ta bladder cancer represents the most
prevalent subtype, accounting for 60%, while T1 and carcinoma in situ (CIS)
comprise the remaining 30% and 10%, respectively. Effective management of NMIBC
hinges on two fundamental principles: complete transurethral resection (TUR) of
the bladder tumor (TUR-B) and intravesical therapy. In the case of NMIBC, the
primary treatment choice involves combining intravesical chemotherapy with
transurethral resection of the bladder, significantly reducing the disease and
its recurrence. Commonly utilized chemotherapy agents include Mitomycin C,
epirubicin, thiotepa, gemcitabine, and doxorubicin. Notably, Bacillus
Calmette–Guerin (BCG) stands out as the most potent intravesical agent and is
preferred for NMIBC patients with an intermediate and high risk of recurrence,
as it is the sole agent with proven efficacy in delaying progression to
muscle-invasive cancer.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment